Thymic Stromal Lymphopoietin Induction Suppresses Lung Cancer Development

Lung cancer is the leading cause of cancer deaths in the United States and across the world. Immunotherapies, which activate tumor-infiltrating cytotoxic T lymphocytes, have demonstrated efficacy for the treatment of advanced-stage lung cancer. However, the potential for harnessing the immune system...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-04, Vol.14 (9), p.2173
Main Authors: Guennoun, Ranya, Hojanazarova, Jennet, Trerice, Kathryn E, Azin, Marjan, McGoldrick, Matthew T, Schiferle, Erik B, Stover, Michael P, Demehri, Shadmehr
Format: Article
Language:English
Subjects:
Adaptive immunity
Adenocarcinoma
Alveoli
Antibodies
Antigens
Carcinogenesis
CD4 antigen
Cytokines
Cytotoxicity
Flow cytometry
Hyperplasia
Immunotherapy
Invasiveness
Lung cancer
Lymphatic system
Lymphocytes
Lymphocytes T
Spleen
Thymic stromal lymphopoietin
Thymus
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is the leading cause of cancer deaths in the United States and across the world. Immunotherapies, which activate tumor-infiltrating cytotoxic T lymphocytes, have demonstrated efficacy for the treatment of advanced-stage lung cancer. However, the potential for harnessing the immune system against the early stages of lung carcinogenesis to prevent cancer development and recurrence remains unexplored. Using a mouse model of lung adenocarcinoma, we investigated the effects of thymic stromal lymphopoietin (TSLP) induction on early cancer development in the lungs. Herein, we demonstrate that systemic TSLP induction suppressed spontaneous lung cancer development in Kras mice. TSLP drove a significant CD4 T cell response to block lung cancer progression from atypical alveolar hyperplasia to adenocarcinoma. Our findings suggest that TSLP can be used in the early stages of lung cancer development to trigger a lasting immunity in the tissue and prevent the development of advanced disease.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14092173